S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
Log in

NASDAQ:RGLSRegulus Therapeutics Stock Price, Forecast & News

$0.77
+0.03 (+3.99 %)
(As of 08/6/2020 09:42 AM ET)
Add
Compare
Today's Range
$0.72
Now: $0.77
$0.78
50-Day Range
$0.68
MA: $0.80
$0.96
52-Week Range
$0.43
Now: $0.77
$1.74
Volume2.23 million shs
Average Volume4.62 million shs
Market Capitalization$16.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More
Regulus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.83 million
Book Value$0.95 per share

Profitability

Net Income$-18,590,000.00
Net Margins-351.32%

Miscellaneous

Employees24
Market Cap$16.30 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable
$0.77
+0.03 (+3.99 %)
(As of 08/6/2020 09:42 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

How has Regulus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Regulus Therapeutics' stock was trading at $0.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGLS stock has increased by 29.1% and is now trading at $0.7746.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Regulus Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Regulus Therapeutics
.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Regulus Therapeutics
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc (NASDAQ:RGLS) released its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.13. The biopharmaceutical company earned $6 million during the quarter, compared to the consensus estimate of $10 million. Regulus Therapeutics had a negative return on equity of 215.33% and a negative net margin of 351.32%.
View Regulus Therapeutics' earnings history
.

What price target have analysts set for RGLS?

3 analysts have issued 12 month price targets for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $1.50. On average, they anticipate Regulus Therapeutics' share price to reach $1.25 in the next year. This suggests a possible upside of 61.4% from the stock's current price.
View analysts' price targets for Regulus Therapeutics
.

What are Wall Street analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (5/19/2020)
  • 2. HC Wainwright analysts commented, "We have assessed Regulus Therapeutics using a discounted cash flow (DCF)-based approach, which ascribes value solely to the RGLS4326 program and the development-related milestone payments slated to be paid by Sanofi contingent upon continued progress with RG-012. Our assumptions include a 15% probability of regulatory approval for 20% probability of continued clinical advancement for RG-012. We also utilize a 15% discount rate, 0.5% terminal growth rate and 30% effective tax rate." (9/6/2019)

Has Regulus Therapeutics been receiving favorable news coverage?

Headlines about RGLS stock have trended negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regulus Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Regulus Therapeutics
.

Who are some of Regulus Therapeutics' key competitors?

What other stocks do shareholders of Regulus Therapeutics own?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the following people:
  • Mr. Joseph P. Hagan, Pres, CEO & Director (Age 50)
  • Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)
  • Mr. Christopher Ray Aker J.D., VP of Legal Affairs & Corp. Sec.
  • Mr. Turner Jenkins, Director & Head of Corp. Devel.

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.77.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $16.30 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-18,590,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Regulus Therapeutics employs 24 workers across the globe.

What is Regulus Therapeutics' official website?

The official website for Regulus Therapeutics is www.regulusrx.com.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.